Chia Yu Chu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6878918/publications.pdf

Version: 2024-02-01

76031 62345 8,223 186 42 84 citations h-index g-index papers 192 192 192 9074 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The impact of atopic dermatitis on health-related quality of life in Taiwan. Journal of the Formosan Medical Association, 2022, 121, 269-277.	0.8	9
2	Analysis of severe cutaneous adverse reactions (SCARs) in Taiwan drug-injury relief system: 18-year results. Journal of the Formosan Medical Association, 2022, 121, 1397-1405.	0.8	8
3	Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A oneâ€year extension study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2175-2184.	2.7	26
4	Patientâ€reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderateâ€toâ€severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 434-443.	1.3	26
5	Healthcare utilization and costs of atopic dermatitis in Taiwan. Journal of the Formosan Medical Association, 2022, , .	0.8	5
6	Taiwanese dermatological association consensus for the definition, classification, diagnosis, and management of urticaria: AÂ2021Âupdate. Journal of the Formosan Medical Association, 2022, 121, 1191-1203.	0.8	5
7	Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis. JAMA Dermatology, 2022, 158, 404.	2.0	90
8	Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit. Scientific Reports, 2022, 12, 7021.	1.6	8
9	Targeting the cutaneous microbiota in atopic dermatitis: â€~AÂnew hope' or â€~attack of the CoNS'?. Clin and Translational Medicine, 2022, 12, e865.	ical 1.7	3
10	Genetic markers for methazolamideâ€induced Stevens–Johnson syndrome and toxic epidermal necrolysis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 764-764.	1.3	1
11	Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study. American Journal of Clinical Dermatology, 2022, 23, 571-585.	3.3	3
12	Clinical, Histopathologic, and Immunohistochemical Features of Patients with IgG/IgA Pemphigus. Biomedicines, 2022, 10, 1197.	1.4	1
13	Cutaneousâ€type pemphigus vulgaris might be a transient subtype in pemphigus vulgaris: a case series. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	0
14	Treatments for Childhood Atopic Dermatitis: an Update on Emerging Therapies. Clinical Reviews in Allergy and Immunology, 2021, 61, 114-127.	2.9	20
15	Intermittent use of biologic agents for the treatment of psoriasis in adults. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 360-367.	1.3	14
16	Taiwanese Dermatological Association consensus for the management of atopic dermatitis: A 2020 update. Journal of the Formosan Medical Association, 2021, 120, 429-442.	0.8	18
17	Coâ€occurrence of <i>TERT</i> promotor mutations with <i>BRAF</i> or <i>NRAS</i> alterations correlates with worse prognosis in melanoma. British Journal of Dermatology, 2021, 184, 390-391.	1.4	3
18	The risk of antiâ€osteoporotic agentâ€induced severe cutaneous adverse drug reactions and their association with HLA. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 712-720.	1.3	8

#	Article	IF	Citations
19	Changing trends of contact allergens: A 40â€year retrospective study from a referral centre in northern Taiwan. Contact Dermatitis, 2021, 85, 39-45.	0.8	5
20	Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. New England Journal of Medicine, 2021, 384, 1101-1112.	13.9	239
21	Supportive care in the acute phase of Stevens–Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphiâ€based consensus. British Journal of Dermatology, 2021, 185, 616-626.	1.4	22
22	New targets in treating granuloma annulare. Journal of Allergy and Clinical Immunology, 2021, 147, 1646-1647.	1.5	3
23	Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet, The, 2021 , 397 , 2151 - 2168 .	6.3	259
24	Functionalizing Collagen with Vesselâ€Penetrating Twoâ€Photon Phosphorescence Probes: A New In Vivo Strategy to Map Oxygen Concentration in Tumor Microenvironment and Tissue Ischemia. Advanced Science, 2021, 8, e2102788.	5.6	5
25	Characteristics of patients with chronic spontaneous urticaria showing early and complete responses to omalizumab. Annals of Allergy, Asthma and Immunology, 2021, 127, 394-395.	0.5	1
26	Impact of Atopic Dermatitis on Work and Activity Impairment in Taiwan. Acta Dermato-Venereologica, 2021, 101, adv00556.	0.6	6
27	Annular drug eruptions. Clinics in Dermatology, 2021, , .	0.8	2
28	Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy. Journal of the Formosan Medical Association, 2020, 119, 230-237.	0.8	8
29	Patients with chronic urticaria have a higher risk of psychiatric disorders: a populationâ€based study. British Journal of Dermatology, 2020, 182, 335-341.	1.4	12
30	Genetic alterations in primary melanoma in Taiwan. British Journal of Dermatology, 2020, 182, 1205-1213.	1.4	31
31	Drug eruptions: Great imitators. Clinics in Dermatology, 2020, 38, 193-207.	0.8	4
32	Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma. Lung Cancer, 2020, 148, 177-178.	0.9	5
33	Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H1-Antihistamines in Asia, Middle-East and Africa: Results from the AWARE-AMAC study. World Allergy Organization Journal, 2020, 13, 100117.	1.6	4
34	Prevalence of baseline comorbidities in patients with atopic dermatitis: A population-based cohort study in Taiwan. JAAD International, 2020, 1 , 50-58.	1.1	14
35	Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results. World Allergy Organization Journal, 2020, 13, 100460.	1.6	30
36	Comment on "Viral reactivation in hospitalized DRESS patients: A retrospective study from a tertiary medical center in the United States― Journal of the American Academy of Dermatology, 2020, 83, e209-e210.	0.6	4

#	Article	IF	Citations
37	Pembrolizumab-induced linear psoriasis. Lung Cancer, 2020, 146, 378-379.	0.9	7
38	Urticaria and the gut. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 381-385.	1.1	9
39	Purpuric drug eruptions induced by EGFR tyrosine kinase inhibitors are associated with IQGAP1â€mediated increase in vascular permeability. Journal of Pathology, 2020, 250, 452-463.	2.1	7
40	The interferonâ€Î³â€induced protein 10/CXCR3 axis is associated with human herpesvirusâ€6 reactivation and the development of sequelae in drug reaction with eosinophilia and systemic symptoms*. British Journal of Dermatology, 2020, 183, 909-919.	1.4	21
41	A study on the knowledge, attitudes, and practices of Asian dermatologists in the management of atopic dermatitis. Dermatologica Sinica, 2020, 38, 67.	0.2	10
42	Using a novel scoring system for paronychia related to oncologic treatments (<scp>SPOT</scp>) for assessing paronychia severity and its correlation with pain index and quality of life. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 204-212.	1.3	13
43	Burden of atopic dermatitis in Asia. Journal of Dermatology, 2019, 46, 825-834.	0.6	61
44	Keeping an eye on the ocular problems in dupilumab clinical trials. British Journal of Dermatology, 2019, 181, 436-437.	1.4	12
45	Ligelizumab for Chronic Spontaneous Urticaria. New England Journal of Medicine, 2019, 381, 1321-1332.	13.9	187
46	Comment on "Abnormal erythrocyte morphology in drug reaction with eosinophilia and systemic symptoms― Journal of the American Academy of Dermatology, 2019, 80, e181.	0.6	1
47	Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer. Lung Cancer, 2019, 129, 110-111.	0.9	9
48	The Medication Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label. Clinical Pharmacology and Therapeutics, 2019, 105, 112-120.	2.3	54
49	Advances in systemic treatment for adults with moderate-to-severe atopic dermatitis. Dermatologica Sinica, 2019, 37, 3.	0.2	16
50	Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. Oncologist, 2018, 23, 891-899.	1.9	36
51	Fever, eosinophilia, and abnormal liver function are early signs suggestive of DRESS: A comparative study between DRESS and MPE. Dermatologica Sinica, 2018, 36, 25-29.	0.2	4
52	Olmutinib-induced palmoplantar keratoderma. British Journal of Dermatology, 2018, 178, e129-e131.	1.4	12
53	Management of Toxicities of Targeted Therapies. , 2018, , 490-500.e3.		2
54	Allergic contact dermatitis caused by acrylates in nail cosmetic products: Case reports and review of the literatures. Dermatologica Sinica, 2018, 36, 218-221.	0.2	3

#	Article	IF	CITATIONS
55	Measuring quality of life in infants, children and adolescents with eczema. British Journal of Dermatology, 2017, 176, 848-849.	1.4	2
56	Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the <scp>TOPICOP</scp> score. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1713-1719.	2.7	52
57	Risk and association of <i>HLA</i> with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology, 2017, 88, 78-86.	1.5	117
58	Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non–Small Cell Lung Cancer. JAMA Dermatology, 2017, 153, 906.	2.0	14
59	Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities. Journal of the Formosan Medical Association, 2017, 116, 413-423.	0.8	21
60	Adult T cell leukemia/lymphoma presenting as multiple necrotic ulcers. Dermatologica Sinica, 2017, 35, 157-158.	0.2	1
61	An investigator-initiated, open-label, single-center, proof-of-concept-study of omalizumab in patients with poorly controlled acute urticaria. Dermatologica Sinica, 2017, 35, 161-162.	0.2	1
62	Contact allergy to methylisothiazolinone/methylchloroisothiazolinone: A retrospective case series in a referral center in northern Taiwan. Dermatologica Sinica, 2017, 35, 201-205.	0.2	2
63	Efficacy of omalizumab treatment for patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in Taiwan. Dermatologica Sinica, 2017, 35, 182-186.	0.2	3
64	Epidemiology and comorbidities of patients with chronic urticaria in Taiwan†A nationwide population-based study. Journal of Dermatological Science, 2017, 88, 192-198.	1.0	44
65	A clinicopathological analysis of 153 acral melanomas and the relevance of mechanical stress. Scientific Reports, 2017, 7, 5564.	1.6	39
66	Frequent <i><scp>PIK</scp>3<scp>CA</scp></i> activating mutations in nipple adenomas. Histopathology, 2017, 70, 195-202.	1.6	13
67	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System. International Journal of Molecular Sciences, 2017, 18, 1243.	1.8	170
68	Treatments for Severe Cutaneous Adverse Reactions. Journal of Immunology Research, 2017, 2017, 1-9.	0.9	40
69	Clinicopathological features and prognosis of patients with de novo versus nevus-associated melanoma in Taiwan. PLoS ONE, 2017, 12, e0177126.	1.1	16
70	Long-term Sequelae of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Acta Dermato-Venereologica, 2016, 96, 525-529.	0.6	81
71	Insulin-Like Growth Factor II mRNA-Binding Protein 3 Expression Correlates with Poor Prognosis in Acral Lentiginous Melanoma. PLoS ONE, 2016, 11, e0147431.	1.1	12
72	Coâ€existence of histopathological features is characteristic in drug reaction with eosinophilia and systemic symptoms and correlates with high grades of cutaneous abnormalities. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 2077-2084.	1.3	17

#	Article	IF	CITATIONS
73	Involvement of hypoxia-inducing factor-1α-dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion Journal of Biological Chemistry, 2016, 291, 27433.	1.6	7
74	A patient with acantholytic pustular purpuric eruption due to gefitinib successfully treated with systemic antibiotics. Dermatologica Sinica, 2016, 34, 166-167.	0.2	4
75	Frequent PIK3CA-activating mutations in hidradenoma papilliferums. Human Pathology, 2016, 55, 57-62.	1.1	17
76	High serum anti-BP180 IgE levels correlate to prominent urticarial lesions in patients with bullous pemphigoid. Journal of Dermatological Science, 2016, 83, 78-80.	1.0	13
77	The Role of Viral Reactivation in Drug Reaction with Eosinophilia and Systemic Symptoms and Other Cutaneous Adverse Drug Reactions (cADRs). Current Dermatology Reports, 2016, 5, 5-11.	1.1	2
78	Unmet medical needs for chronic spontaneous urticaria patients: highlighting the realâ€life clinical practice in Taiwan. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 41-49.	1.3	9
79	G9a/RelB regulates self-renewal and function of colon-cancer-initiating cells by silencing Let-7b and activating the K-RAS/ \hat{l}^2 -catenin pathway. Nature Cell Biology, 2016, 18, 993-1005.	4.6	29
80	Autoantibodies against members of the plakin family in severe drug eruptions: does the phenomenon matter?. British Journal of Dermatology, 2016, 175, 866-867.	1.4	0
81	Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non–Small Cell Lung Cancer. JAMA Dermatology, 2016, 152, 340.	2.0	29
82	Taiwanese Dermatological Association consensus for the definition, classification, diagnosis, and management of urticaria. Journal of the Formosan Medical Association, 2016, 115, 968-980.	0.8	12
83	<i>TERT</i> promoter mutations in periocular carcinomas: implications of ultraviolet light in pathogenesis. British Journal of Ophthalmology, 2016, 100, 274-277.	2.1	13
84	Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan. Journal of the Formosan Medical Association, 2016, 115, 121-127.	0.8	33
85	Treatment strategies of epidermal growth factor receptor inhibitor-induced skin toxicities: pre-emptive or reactive?. Annals of Translational Medicine, 2016, 4, 318-318.	0.7	3
86	Taiwanese Dermatological Association consensus for the management of atopic dermatitis. Dermatologica Sinica, 2015, 33, 220-230.	0.2	16
87	Human herpes virus reactivations and dynamic cytokine profiles in patients with cutaneous adverse drug reactions– a prospective comparative study. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 568-575.	2.7	49
88	Sequelae in 145 patients with drugâ€induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: Survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (<scp>ASCAR</scp>). Journal of Dermatology, 2015, 42, 276-282.	0.6	97
89	First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid. British Journal of Dermatology, 2015, 173, 302-304.	1.4	61
90	IMP-3 Promotes Migration and Invasion of Melanoma Cells by Modulating the Expression of HMGA2 and Predicts Poor Prognosis in Melanoma. Journal of Investigative Dermatology, 2015, 135, 1065-1073.	0.3	40

#	Article	IF	Citations
91	Liver injury in patients with DRESS: A clinical study of 72 cases. Journal of the American Academy of Dermatology, 2015, 72, 984-991.	0.6	59
92	Contact dermatitis to topical medicaments: A retrospective study from a medical center in Taiwan. Dermatologica Sinica, 2015, 33, 181-186.	0.2	10
93	First-line Combination Therapy with Rituximab and Corticosteroids is Effective and Safe for Pemphigus. Acta Dermato-Venereologica, 2014, 94, 472-473.	0.6	32
94	<i><scp>TERT</scp></i> promoter mutation is uncommon in acral lentiginous melanoma. Journal of Cutaneous Pathology, 2014, 41, 504-508.	0.7	37
95	Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. Journal of the American Academy of Dermatology, 2014, 70, 539-548.	0.6	90
96	Paraneoplastic pemphigus: A retrospective case series in a referral center in northern Taiwan. Dermatologica Sinica, 2014, 32, 1-6.	0.2	9
97	Spectrometric analysis of mercury content in 549 skin-lightening products: Is mercury toxicity aAhiddenAglobal health hazard?. Journal of the American Academy of Dermatology, 2014, 70, 281-287.e3.	0.6	83
98	Analysis of melanomaâ€related micro <scp>RNA</scp> s expression during the spontaneous regression of cutaneous melanomas in MeLiM pigs. Pigment Cell and Melanoma Research, 2014, 27, 668-670.	1.5	4
99	Clinical pattern of liver injury in drug reaction with eosinophilia and systemic symptoms (DRESS): a retrospective study in Taiwan. Clinical and Translational Allergy, 2014, 4, P18.	1.4	0
100	Differential cytokine/chemokine profiles and reactivation of human herpes viruses in various forms of cutaneous adverse drug reactions. A comparative study in Taiwan. Clinical and Translational Allergy, 2014, 4, P20.	1.4	0
101	Sarcoidal alopecia mimicking discoid lupus erythematosus: Report of a case and review of the literature. Dermatologica Sinica, 2014, 32, 43-46.	0.2	1
102	Chronic actinic dermatitis: A clinical study of 15 cases in northern Taiwan. Dermatologica Sinica, 2014, 32, 82-86.	0.2	8
103	Correlation of thiopurine methyltransferase and inosine triphosphate pyrophosphatase polymorphisms and adverse effects induced by azathioprine treatment in Taiwanese dermatology patients. Dermatologica Sinica, 2014, 32, 13-18.	0.2	9
104	Consensus guidelines for the management of atopic dermatitis: An <scp>A</scp> sia– <scp>P</scp> acific perspective. Journal of Dermatology, 2013, 40, 160-171.	0.6	64
105	Induction of chemokine receptor CXCR4 expression by transforming growth factor- \hat{l}^21 in human basal cell carcinoma cells. Journal of Dermatological Science, 2013, 72, 123-133.	1.0	10
106	Reply to: "Using a diagnostic score when reporting the long-term sequelae of the drug reaction with eosinophilia and systemic symptomsâ€. Journal of the American Academy of Dermatology, 2013, 69, 1060-1062.	0.6	13
107	Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: A retrospective cohort study from Taiwan. Journal of the American Academy of Dermatology, 2013, 68, 459-465.	0.6	145
108	Drug reaction with eosinophilia and systemic symptoms: A drug-induced hypersensitivity syndrome with variable clinical features. Dermatologica Sinica, 2013, 31, 196-204.	0.2	48

#	Article	IF	CITATIONS
109	Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. British Journal of Dermatology, 2013, 169, 1071-1080.	1.4	652
110	Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Review of Anticancer Therapy, 2013, 13, 721-728.	1.1	80
111	Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib. Journal of Clinical Oncology, 2013, 31, e335-e337.	0.8	6
112	The presence of clusters of plasmacytoid dendritic cells is a helpful feature for differentiating lupus panniculitis from subcutaneous panniculitisâ€like ⟨scp⟩T⟨/scp⟩â€cell lymphoma. Histopathology, 2013, 62, 1057-1066.	1.6	57
113	CCN2 inhibits lung cancer metastasis through promoting DAPK-dependent anoikis and inducing EGFR degradation. Cell Death and Differentiation, 2013, 20, 443-455.	5.0	37
114	Localized AL Amyloidosis in a Patient with Diffuse Large B-cell Lymphoma of the Breast. Acta Dermato-Venereologica, 2012, 92, 284-285.	0.6	3
115	Fixed-drug eruption: A retrospective study in a single referral center in northern Taiwan. Dermatologica Sinica, 2012, 30, 11-15.	0.2	25
116	The pharmacological mechanisms of omalizumab in patients with very high IgE levelsâ€"Clues from studies on atopic dermatitis. Dermatologica Sinica, 2012, 30, 147-153.	0.2	16
117	Skin as an immune organ. Dermatologica Sinica, 2012, 30, 119-120.	0.2	4
118	Nanohybrids of Silver Particles Immobilized on Silicate Platelet for Infected Wound Healing. PLoS ONE, 2012, 7, e38360.	1.1	25
119	The role of IL-8 in the SDF- $1\hat{l}\pm$ /CXCR4-induced angiogenesis of laryngeal and hypopharyngeal squamous cell carcinoma. Oral Oncology, 2012, 48, 507-515.	0.8	19
120	Skin manifestations of gefitinib and the association with survival of advanced non-small-cell lung cancer in Taiwan. Dermatologica Sinica, 2011, 29, 13-18.	0.2	4
121	Chronic Idiopathic Urticaria in Taiwan: A Clinical Study of Demographics, Aggravating Factors, Laboratory Findings, Serum Autoreactivity and Treatment Response. Journal of the Formosan Medical Association, 2011, 110, 175-182.	0.8	20
122	Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway. British Journal of Dermatology, 2011, 164, 38-46.	1.4	15
123	miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. Journal of Clinical Investigation, 2011, 121, 3442-3455.	3.9	126
124	Drug Reaction With Eosinophilia and Systemic Symptoms. Archives of Dermatology, 2010, 146, 1373.	1.7	274
125	MicroRNA-519c Suppresses Hypoxia-Inducible Factor-1α Expression and Tumor Angiogenesis. Cancer Research, 2010, 70, 2675-2685.	0.4	187
126	Common risk allele in aromatic antiepileptic-drug induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics, 2010, 11, 349-356.	0.6	277

#	Article	IF	CITATIONS
127	Unique Epitopes on ClµmX in IgE–B Cell Receptors Are Potentially Applicable for Targeting IgE-Committed B Cells. Journal of Immunology, 2010, 184, 1748-1756.	0.4	38
128	A randomized, double-blind, active-controlled, parallel-group pilot study to compare the efficacy and sedative effects of desloratadine 5Âmg with levocetirizine 5 mg in the treatment of chronic idiopathic urticaria. Journal of the American Academy of Dermatology, 2010, 63, e100-e102.	0.6	10
129	Linear IgA bullous dermatosis: a clinical study of 16 cases at National Taiwan University Hospital. Dermatologica Sinica, 2010, 28, 21-26.	0.2	5
130	Stromal cell-derived factor-1α (SDF-1α/CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1/2–NF-βB/interleukin-6 pathway. Carcinogenesis, 2009, 30, 205-213.	1.3	48
131	Dapsone hypersensitivity syndrome in non-leprosy patients: A retrospective study of its incidence in a tertiary referral center in Taiwan. Journal of Dermatological Treatment, 2009, 20, 340-343.	1.1	23
132	Tumor-Associated Macrophage-Induced Invasion and Angiogenesis of Human Basal Cell Carcinoma Cells by Cyclooxygenase-2 Induction. Journal of Investigative Dermatology, 2009, 129, 1016-1025.	0.3	292
133	Oxcarbazepineâ€induced Stevens–Johnson syndrome in a patient with <i>HLAâ€B*1502</i> genotype. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 702-703.	1.3	44
134	Systematized linear porokeratosis: A rare variant of diffuse porokeratosis with good response to systemic acitretin. Journal of the American Academy of Dermatology, 2009, 60, 713-715.	0.6	23
135	Polymorphisms of MTHFR gene associated with livedoid vasculopathy in Taiwanese population. Journal of Dermatological Science, 2009, 54, 214-216.	1.0	10
136	Connective tissue growth factor (CTGF) and cancer progression. Journal of Biomedical Science, 2008, 15, 675-685.	2.6	118
137	Secretome analysis of novel IgEâ€binding proteins from <i>Penicillium citrinum</i> . Proteomics - Clinical Applications, 2008, 2, 33-45.	0.8	19
138	Contact sensitization to metals in Taiwan. Contact Dermatitis, 2008, 59, 353-360.	0.8	42
139	Magnetic resonance imaging as a diagnostic tool for extensive lipodermatosclerosis. Journal of the American Academy of Dermatology, 2008, 58, 525-527.	0.6	8
140	Severe Purpuric Xerotic Dermatitis Associated With Gefitinib Therapy. Archives of Dermatology, 2008, 144, 269-70.	1.7	16
141	Cutaneous Polyarteritis Nodosa in a Patient With Fabry Disease. Archives of Dermatology, 2008, 144, 122-3.	1.7	3
142	CXCL12/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1 pathway. Carcinogenesis, 2008, 29, 1519-1527.	1.3	91
143	Involvement of Hypoxia-inducing Factor- $1\hat{l}$ ±-dependent Plasminogen Activator Inhibitor-1 Up-regulation in Cyr61/CCN1-induced Gastric Cancer Cell Invasion. Journal of Biological Chemistry, 2008, 283, 15807-15815.	1.6	58
144	Cysteine-Rich 61 (CCN1) Enhances Chemotactic Migration, Transendothelial Cell Migration, and Intravasation by Concomitantly Up-Regulating Chemokine Receptor 1 and 2. Molecular Cancer Research, 2007, 5, 1111-1123.	1.5	43

#	Article	IF	Citations
145	Elevated Expression of Cyr61 Enhances Peritoneal Dissemination of Gastric Cancer Cells through Integrin $\hat{1}\pm2\hat{1}^21$. Journal of Biological Chemistry, 2007, 282, 34594-34604.	1.6	45
146	Carcinoma Erysipeloides From Ovarian Clear-Cell Carcinoma. Journal of Clinical Oncology, 2007, 25, 5828-5830.	0.8	7
147	Multiple eruptive dermatofibromas in a patient withÂdermatomyositis taking prednisolone andÂmethotrexate. Journal of the American Academy of Dermatology, 2007, 57, S81-S84.	0.6	23
148	Paraneoplastic Pemphigus and Bronchiolitis Obliterans in a Patient with Splenic B-cell Lymphoma. Journal of the Formosan Medical Association, 2007, 106, 768-773.	0.8	8
149	The Minimal Erythema Dose of Broadband Ultraviolet B in Taiwanese. Journal of the Formosan Medical Association, 2007, 106, 975-978.	0.8	19
150	Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma and Immunology, 2007, 98, 51-56.	0.5	80
151	Mutation of keratin 9 (R163W) in a family with epidermolytic palmoplantar keratoderma and knuckle pads. Journal of Dermatological Science, 2007, 45, 63-65.	1.0	12
152	IL-6 induces AGS gastric cancer cell invasionvia activation of the c-Src/RhoA/ROCK signaling pathway. International Journal of Cancer, 2007, 120, 2600-2608.	2.3	127
153	Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1α-directed invasion of human basal cell carcinoma cells. Oncogene, 2007, 26, 2491-2501.	2.6	72
154	Adult pityriasis lichenoides-like mycosis fungoides with high density of CD8-positive T-lymphocytic infiltration. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 401-402.	1.3	12
155	An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 070209222700037-???.	1.3	28
156	Eccrine squamous syringometaplasia associated with sunitinib therapy. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 1136-1137.	1.3	24
157	Allergic contact dermatitis due to sodium metabisulfite in a bleaching cream. Contact Dermatitis, 2007, 56, 123-124.	0.8	16
158	Dopamine-induced apoptosis in human melanocytes involves generation of reactive oxygen species. British Journal of Dermatology, 2006, 154, 1071-1079.	1.4	39
159	Antineutrophil Cytoplasmic Antibody–Positive Cutaneous Leukocytoclastic Vasculitis Associated With Propylthiouracil Therapy. Archives of Dermatology, 2006, 142, 879-80.	1.7	12
160	Dapsone as a Potential Treatment for Cutaneous Rosai-Dorfman Disease With Neutrophilic Predominance. Archives of Dermatology, 2006, 142, 428.	1.7	22
161	Concomitant contact allergy to the resins, reactive diluents and hardener of a bisphenol A/F-based epoxy resin in subway construction workers. Contact Dermatitis, 2006, 54, 131-139.	0.8	29
162	Cyclooxygenase-2 Overexpression in Human Basal Cell Carcinoma Cell Line Increases Antiapoptosis, Angiogenesis, and Tumorigenesis. Journal of Investigative Dermatology, 2006, 126, 1143-1151.	0.3	59

#	Article	IF	Citations
163	Effect of Connective Tissue Growth Factor on Hypoxia-Inducible Factor 1α Degradation and Tumor Angiogenesis. Journal of the National Cancer Institute, 2006, 98, 984-995.	3.0	74
164	The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. British Journal of Dermatology, 2005, 152, 396-399.	1.4	47
165	Docetaxel-induced recall dermatitis on previous laser treatment sites. British Journal of Dermatology, 2005, 153, 441-443.	1.4	10
166	HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4134-4139.	3.3	1,110
167	1,2-Ethanedithiol-induced Erythema Multiforme-like Contact Dermatitis. Acta Dermato-Venereologica, 2004, 84, 393-396.	0.6	14
168	Digital infarcts showing microangiopathy in adult dermatomyositis suggest severe pulmonary involvement and poor prognosis. British Journal of Dermatology, 2004, 150, 1214-1216.	1.4	16
169	Interleukin-6 Induced Basic Fibroblast Growth Factor-Dependent Angiogenesis in Basal Cell Carcinoma Cell Line via JAK/STAT3 and Pl3-Kinase/Akt Pathways. Journal of Investigative Dermatology, 2004, 123, 1169-1175.	0.3	112
170	Disseminated human papillomavirus type 11 infection in a patient with pemphigus vulgaris: Confirmed by DNA analysis. Journal of the American Academy of Dermatology, 2004, 51, S190-S193.	0.6	16
171	Topical tacrolimus therapy for localized bullous pemphigoid. British Journal of Dermatology, 2003, 149, 1079-1081.	1.4	29
172	Transformation between Kaposiform Hemangioendothelioma and Tufted Angioma. Dermatology, 2003, 206, 334-337.	0.9	75
173	Vesicant-type Reaction Due to Docetaxel Extravasation. Acta Dermato-Venereologica, 2003, 83, 467-468.	0.6	14
174	Chemotherapy-induced Recall Dermatitis on a Previously Scalded Wound in a Patient with Acute Myeloid Leukaemia. Acta Dermato-Venereologica, 2003, 83, 382-383.	0.6	5
175	Allergic Contact Dermatitis from Etofenamate without Cross-Sensitization to Other Anthranilic Acid Derivatives. Dermatology, 2003, 206, 341-342.	0.9	6
176	Fixed Erythrodysaesthesia Plaque due to Gemcitabine and Epirubicin Treatment. Acta Dermato-Venereologica, 2002, 82, 147-148.	0.6	9
177	Methimazole-induced Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis and Lupus-like Syndrome with a Cutaneous Feature of Vesiculo-bullous Systemic Lupus Erythematosus. Acta Dermato-Venereologica, 2002, 82, 206-208.	0.6	32
178	HLA-Cw6 specificity and polymorphic residues are associated with susceptibility among Chinese psoriatics in Taiwan. Archives of Dermatological Research, 2002, 294, 214-220.	1.1	27
179	The Phosphotidyl Inositol 3-Kinase/Akt Signal Pathway Is Involved in Interleukin-6-mediated Mcl-1 Upregulation and Anti-apoptosis Activity in Basal Cell Carcinoma Cells. Journal of Investigative Dermatology, 2002, 119, 1121-1127.	0.3	42
180	Allergic contact dermatitis from acrylonitrile. American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society, 2001, 12, 113-114.	0.4	4

#	Article	IF	CITATIONS
181	Inflammation of Seborrheic Keratoses due to Docetaxel Treatment. Acta Dermato-Venereologica, 2001, 81, 316-317.	0.6	10
182	Acute Generalized Exanthematous Pustulosis due to Teicoplanin. Dermatology, 2001, 202, 141-142.	0.9	22
183	Allergic contact dermatitis from triethanolamine in a sunscreen. Contact Dermatitis, 2001, 44, 59-59.	0.8	29
184	Lichen planus with xanthomatous change in a patient with primary biliary cirrhosis. British Journal of Dermatology, 2000, 142, 377-378.	1.4	22
185	Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. British Journal of Dermatology, 2000, 142, 808-811.	1.4	65
186	Asian type atopic dermatitis. , 0, 2, 48.		0